STOCK TITAN

newcleo prospectus lists up to 218M ordinary shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
424B3

Rhea-AI Filing Summary

newcleo plc (NWCL) issued a prospectus supplement listing up to 217,834,936 ordinary shares and up to 9,146,717 ordinary shares underlying warrants. It updates the prospectus with a Form 6-K furnished November 18, 2026, and says it should be read together with the prospectus.

On November 17, 2026, ordinary shares closed at $4.01 per share and Company Warrants at $0.38 per warrant.

Ordinary shares listed Up to 217,834,936 shares Prospectus supplement cover
Ordinary shares underlying warrants listed Up to 9,146,717 shares Prospectus supplement cover
Ordinary share closing price $4.01 per share November 17, 2026
Company Warrant closing price $0.38 per warrant November 17, 2026
prospectus supplement regulatory
"PROSPECTUS SUPPLEMENT NO. 1"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
ordinary shares technical
"UP TO 217,834,936 ORDINARY SHARES"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
Company Warrants technical
"our warrants (“Company Warrants”)"
Form 6-K regulatory
"Report on Form 6-K, furnished to the SEC"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
Offering Type supplement
Securities Offered Ordinary shares and ordinary shares underlying warrants
Offering Amount Up to 217,834,936 ordinary shares and up to 9,146,717 ordinary shares underlying warrants

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many NWCL ordinary shares and warrant-underlying shares are listed in the supplement?

The cover lists up to 217,834,936 ordinary shares and up to 9,146,717 ordinary shares underlying warrants.

What were NWCL’s closing prices on November 17, 2026?

Ordinary shares closed at $4.01 per share, and Company Warrants closed at $0.38 per warrant.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

Filed Pursuant to Rule 424(b)(3)
Registration No. 333-299328

 

PROSPECTUS SUPPLEMENT NO. 1
(to Prospectus dated October 16, 2026)

 

newcleo plc

 

UP TO 217,834,936 ORDINARY SHARES

 

UP TO 9,146,717 ORDINARY SHARES UNDERLYING WARRANTS

 

 

 

This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form F-1 (as supplemented or amended from time to time, the “Prospectus”) (Registration No. 333-299328). 

 

This prospectus supplement is being filed to update, amend and supplement the information included in the Prospectus with the information contained in our Report on Form 6-K, furnished to the Securities and Exchange Commission (the “SEC”) on November 18, 2026 (the “Form 6-K”). Accordingly, we have attached the Form 6-K to this prospectus supplement.

 

This prospectus supplement is not complete without the Prospectus. This prospectus supplement should be read in conjunction with the Prospectus, which is to be delivered with this prospectus supplement, and is qualified by reference thereto, except to the extent that the information in this prospectus supplement updates or supersedes the information contained in the Prospectus. Please keep this prospectus supplement with your Prospectus for future reference.

 

Our ordinary shares, par value $0.02288 per share (“Ordinary Shares”), and our warrants (“Company Warrants”) are listed on The Nasdaq Stock Market LLC (“Nasdaq”) under the trading symbols “NWCL” and “NWCLW,” respectively. On November 17, 2026, the closing price of our Ordinary Shares on Nasdaq was $4.01 per share and the closing price of our Company Warrants on Nasdaq was $0.38 per warrant.

 

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 26 of the Prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the U.S. Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these securities or determined if the Prospectus or this prospectus supplement is truthful or complete. Any representation to the contrary is a criminal offense.

 

 

 

 The date of this prospectus supplement is November 18, 2026.

 

 

 

 

 

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16
OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2026

 

Commission file number: 001-43479

 

newcleo plc
(Exact name of Registrant as specified in its charter)

 

55 South Audley Street

London, W1K 2QH

United Kingdom

+39 011 5139700

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒ Form 40-F ☐

 

 

 

 

 

TABLE OF CONTENTS

 

Exhibit

 

99.1 Press Release dated November 18, 2026 – newcleo plc Provides Third Quarter 2026 Business and Preliminary Financial Update

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

newcleo plc
 
By: /s/ Stefano Buono
  Name: Stefano Buono
  Title: Chief Executive Officer and Director


Date: November 18, 2026

 

 

Keep reading